| Name | Title | Contact Details |
|---|
Aerolase designs, manufactures and markets the LightPod family of lasers, which represent a technology breakthrough in the field of laser medicine. The result is a new generation of aesthetic and dermatology lasers, built on the proven safety and versatility of gold-standard medical laser modalities. LightPod lasers deliver the highest power for aesthetic & dermatology treatments with uniquely optimized laser pulse parameters based on clinical research. They lead the industry with an unprecedented combination of Efficacy, Safety, Versatility, and Return on Investment.
Dexta Corporation is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Located in Twinsburg Ohio, Edgepark is the nation's leading provider of medical supplies including ostomy, wound care, incontinence and diabetic supplies. Edgepark Surgical is a family-owned business driven by culture and values. Four fully-stocked
Great Plains Regional Medical Center is a North Platte, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.